Diabetes

Findings highlight the need for evidence-based strategies to avoid being obese or overweight for patients with type 1 diabetes, which is often considered a disease of thin individuals.

The risk of new-onset cardiometabolic diseases was significantly elevated post-COVID-19 infection compared to pre-COVID-19 infection.

Declining and inconsistent use of blood-pressure, glucose-, and lipid-lowering medications for those with type 2 diabetes suggests treatment gaps, investigators say.

Pharmacies have long embraced innovation and technology, with early adoption of telehealth and digital platforms.

More than 90 minutes of varied sleep time may also increase a person’s risk of developing hardened arteries.

Study results indicate that exercising, following a high-quality diet, limiting alcohol intake, maintaining a healthy body weight, and not smoking protects those with type 2 diabetes.

In a fact sheet released by the White House, President Joseph Biden called a $35 monthly cap on insulin for all Americans a “commonsense, life-saving protection.”

The knowledge of clinical pharmacists can help protect kidney function and prevent the development of acute kidney injury in ICU patients.

The CBD gummy market is being fueled by the desire for alternative, natural treatment options.

B12 deficiency is often due to a lack of consumption of vitamin B12 rich foods or malabsorption.

Mandy Reece, PharmD, CDCES, BC-ADM, BCACP, FADCES, vice chair and associate professor in the department of pharmacy practice at Philadelphia College of Osteopathic Medicine, discusses diabetes care, change in treatment, and management.

Intensive health behavior and lifestyle treatment is the most effective behavioral treatment for childhood obesity.

A community-based multidisciplinary team can have a significant impact addressing health disparities and diabetes management.

Spinal cord stimulation has been used for 50 years to effectively manage chronic pain without opioids.

Case studies address questions about a patient with type 2 diabetes and a patient who is curious about nicotine replacement therapy.

Cases address questions about glycated hemoglobin A1C and hypoglycemia management.

Findings suggest cancer may have overtaken cardiovascular disease as a leading cause of death in individuals with type 2 diabetes.

In a phase 3 trial, empagliflozin significantly reduced the risk of kidney disease progression or cardiovascular death in adults with chronic kidney disease by 28% compared with placebo.

Community pharmacies are an untapped resource in rural areas but need to market their services to effect changes in public health.

High cost-sharing is a large barrier to insulin access, as are aspects of the Inflation Reduction Act of 2022.

The oral SGLT2 inhibitor has been shown to reduce blood sugar and improve glycemic control as an adjunct to diet and exercise.

The popularity of intermittent fasting, or time-restricted eating patterns, may not help control weight as well as other dieting methods.

Individuals with higher caffeine levels were less likely to have liver fibrosis, while higher levels of non-caffeine coffee components were associated with reduced fatty liver index scores.

An app using AI to evaluate blood sugar data, concerning trends, and recommend management tools will be a part of a clinical trial in 2024 for further assessment.

It is too early to know how patients could potentially change their microbiome to reduce their diabetes risk.